A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

NCT05238883 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Cancer
Renal Cell Carcinoma
Melanoma
Sarcoma
Testicular Germ Cell Tumor
Cervical Cancer
Mesothelioma
Non Small Cell Lung Cancer
Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: HFB200301
DRUG: Tislelizumab

Sponsor

HiFiBiO Therapeutics